Holen Sie sich die Stockscreener-App
101.10
0.35%
0.35
Schlusskurs vom Vortag:
$100.75
Offen:
$101.47
24-Stunden-Volumen:
1.37M
Relative Volume:
0.68
Marktkapitalisierung:
$20.12B
Einnahmen:
$4.81B
Nettoeinkommen (Verlust:
$1.19B
KGV:
16.96
EPS:
5.961
Netto-Cashflow:
$1.17B
1W Leistung:
-6.73%
1M Leistung:
-2.25%
6M Leistung:
+17.76%
1J Leistung:
+44.41%
1-Tages-Spanne:
$100.53
$103.18
1-Wochen-Bereich:
$97.25
$109.48
52-Wochen-Spanne:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
101.10 | 20.05B | 4.81B | 1.19B | 1.17B | 5.961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte’s weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10) By Reuters - Investing.com
Incyte Corporation $INCY Shares Sold by Sound Shore Management Inc CT - MarketBeat
LSV Asset Management Buys 124,266 Shares of Incyte Corporation $INCY - MarketBeat
Illinois Municipal Retirement Fund Sells 15,073 Shares of Incyte Corporation $INCY - MarketBeat
Do Wall Street Analysts Like Incyte Corporation Stock? - inkl
INCY: Stifel Raises Price Target to $120, Maintains Buy Rating | - GuruFocus
Incyte shifts course on downtown Wilmington project, sells Bracebridge buildings as state incentives face scrutiny - Delaware LIVE News
Incyte selling buildings and cutting back space at future downtown headquarters - Delaware Business Now
Incyte selling buildings and cut back space at future downtown headquarters - Delaware Business Now
Royal Bank Of Canada Cuts Incyte (NASDAQ:INCY) Price Target to $92.00 - MarketBeat
Incyte (INCY): RBC Capital Lowers Price Target to USD 92 | INCY Stock News - GuruFocus
Incyte (INCY) Analyst Ratings Update: Wells Fargo Lowers Price Target | INCY Stock News - GuruFocus
Wells Fargo & Company Cuts Incyte (NASDAQ:INCY) Price Target to $101.00 - MarketBeat
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow - Finviz
Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Call Transcript - Insider Monkey
INCY: HC Wainwright & Co. Reiterates Buy Rating, Maintains $135 Price Target | INCY Stock News - GuruFocus
Incyte Faces Growing Pains As It Looks To Build Post-Jakafi Foundation - Citeline News & Insights
Incyte Shares Surge on Strong Revenue Performance and Pipeline Progress - AD HOC NEWS
Incyte Faces Jakafi Patent Cliff; Focus on Opzelura and Advancing Pipeline to Offset Losses - Morningstar
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus
Incyte: Fourth Quarter Earnings Overview - Bitget
Incyte (INCY) Shares Fall After Q4 Earnings Miss and Weak 2026 O - GuruFocus
Incyte Corporation Reports Strong 2025 Fiscal Results and Provides 2026 Guidance - AlphaStreet News
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte (INCY) Reports Strong Q4 and Annual Revenue Growth - GuruFocus
Incyte Q4 Earnings Call Highlights - Yahoo Finance
Incyte Corp (INCY) Q4 2025 Earnings Call Highlights: Strong Reve - GuruFocus
Incyte (INCY) Shares Fall After Q4 Earnings Miss and Weak 2026 Outlook - GuruFocus
Jefferies reiterates Buy rating on Incyte stock, maintains $120 price target - Investing.com Canada
Why Incyte (INCY) Stock Is Nosediving - Finviz
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - sharewise.com
Incyte (INCY) Releases Product Revenue and Expense Guidance for 2026 - GuruFocus
Incyte (NASDAQ:INCY) Shares Gap Down Following Weak Earnings - MarketBeat
Truist Securities reiterates Hold rating on Incyte stock, maintains $103 target - Investing.com
Incyte Q4 2025 slides: Revenue surges 28%, stock dips on EPS miss - Investing.com
Incyte (INCY) Q4 2025 Earnings Call Transcript - The Globe and Mail
Incyte (INCY) Faces Challenges with Opzelura as Jakafi Patent Expiry Looms - GuruFocus
Earnings call transcript: Incyte’s Q4 2025 revenue beats estimates, stock dips - Investing.com
Incyte (INCY) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Incyte (NASDAQ:INCY) Posts Quarterly Earnings Results, Misses Estimates By $0.16 EPS - MarketBeat
Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales - Finviz
Incyte (INCY) Reports Strong Q4 Revenue and Promising Pipeline G - GuruFocus
Incyte Corp. (NASDAQ:INCY) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss - ChartMill
Incyte (INCY) Q4 Earnings Lag Estimates - Yahoo Finance
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns - Reuters
Incyte: Q4 Earnings Snapshot - kens5.com
Incyte (INCY) Q4 Revenue Surpasses Estimates Despite EPS Miss - GuruFocus
Incyte shares fall as Q4 earnings miss overshadows revenue beat - Investing.com
Incyte shares fall as Q4 earnings miss overshadows revenue beat By Investing.com - Investing.com South Africa
Incyte earnings missed by $0.11, revenue topped estimates - Investing.com
Incyte earnings missed by $0.11, revenue topped estimates By Investing.com - Investing.com South Africa
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):